Rhythm Pharmaceuticals (RYTM) PT Lowered to $16 at Goldman Sachs, Following Earnings
Get Alerts RYTM Hot Sheet
Price: $38.15 -3.93%
Rating Summary:
9 Buy, 0 Hold, 0 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Rating Summary:
9 Buy, 0 Hold, 0 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Goldman Sachs analyst Graig Suvannavejh lowered the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $16.00 (from $23.00) while maintaining a Sell rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MarineMax (HZO) PT Lowered to $35 at Stifel
- Amazon.com (AMZN) PT Raised to $215 at UBS
- Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Goldman Sachs, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!